The tightening of regulatory requirements in Russia, the Eurasian Economic Union (EAEU) countries, and global markets is making toxicological assessment not just a formality, but a cornerstone of the registration dossier. While previously a manufacturer could often suffice with a material certificate, regulators now demand a comprehensive analysis of biological effects, factoring in chemical composition and clinical application. Industry experts highlight that the risk-based approach embedded in modern standards is shifting toxicology from the realm of "paper" safety into the domain of evidence-based medicine.
What Has Changed in Regulation
Effective January 1, 2026, new editions of the general safety and performance requirements for medical devices, harmonized with the international standard ISO 10993, come into force within the EAEU. Key changes include:
-
Chemical characterization as a mandatory first step. Before biological testing, the manufacturer must conduct an analytical study of the device's composition, including identifying leachable and migrating substances in simulated-use media.
-
A move away from excessive animal testing. Where possible, preference is given to in vitro methods (cytotoxicity, genotoxicity on cell cultures) and computational methods (toxicokinetics modeling, read-across).
-
Toxicological Risk Assessment (TRA). It is no longer sufficient to simply state the presence of cytotoxicity. A calculation of the permissible exposure dose for the patient is required, considering the contact duration (limited, prolonged, permanent) and the nature of contact (skin, mucosal tissue, blood, bone tissue).
The Three Pillars of Modern Toxicological Research
1. Chemical Profile: Looking "Inside" the Material
Starting a study without knowing what might "leach" out of a plastic, metal, or ceramic is now considered a gross methodological error. GC-MS, HPLC, and ICP-MS analysis can detect traces of monomers, plasticizers (phthalates), heavy metal ions, and residual solvents. If chemical analysis reveals no compounds with known toxicity at clinically significant concentrations, some biological tests can be omitted entirely, with a scientific justification provided in the risk assessment file.
2. Biological Testing: From Cytotoxicity to Chronic Toxicity
The battery of tests is strictly selected according to the device's intended purpose:
-
Cytotoxicity (ISO 10993-5): A screening test for all medical devices. A positive in vitro result almost always means registration denial, unless the specificity of a chemical reaction (e.g., pH shift in dental cements during setting) is proven.
-
Sensitization and Irritation (ISO 10993-10, 23): For devices contacting the skin and mucous membranes. Priority is given to reconstructed human epidermis (RhE) models over rabbit tests.
-
Systemic Toxicity (acute, subchronic, chronic tests): For implants and long-term contact devices. Here, the push to reduce animal testing is strongest, driving demand for microfluidic "organ-on-a-chip" technologies.
-
Genotoxicity, Carcinogenicity, Reproductive Toxicity: Mandatory if chemical analysis has revealed the presence of CMR Class 1A/1B substances.
3. Toxicological Risk Assessment (TRA)
This is the most intellectually demanding stage. A toxicologist consolidates chemical analysis and bio-test data, calculates the Tolerable Intake (TI), and compares it to the actual dose a patient might receive. The final document (Toxicological Risk Assessment Report) is not just a certificate but the main argument for regulators, proving that "the toxicological burden is acceptable for the given clinical application."
Why Toxicological Studies Have Become Critically Important: Four Reasons
1. Clinical Safety: Lessons from the Past
Global practice knows dozens of product recall cases where insufficient toxicological control led to tragedies. From stents with allergenic polymers to metal-on-metal hip implants causing cobalt intoxication. Toxicology during registration is the barrier that prevents systemic organ damage, carcinogenic effects, and anaphylactic reactions, which are not always detected during clinical trials due to small sample sizes.
2. The Regulatory Filter: No Biocompatibility, No Registration
National and international regulators (Roszdravnadzor, FDA, China's NMPA) increasingly demand not just a "checkmark" on a list, but a scientific justification for every test. Submitting a registration dossier with incomplete toxicological justification leads to a frozen procedure, lengthy correspondence, and direct financial losses.
3. Technological Audit of Production
Toxicological problems often expose hidden manufacturing defects: an incorrect sterilization regime that can generate toxic byproducts (e.g., ethylene oxide and 2-chloroethanol), or raw material contamination. Thus, toxicology acts as an indicator of the maturity of the quality management system.
4. Ethical and Reputational Component
The shift toward humane, animal-free testing methods is becoming a competitive advantage for Western and Asian markets. Moreover, legal precedent in several countries shows that a manufacturer who failed to conduct an adequate toxicological risk assessment at the product launch stage bears increased liability for any harm to health.
Practical Recommendations for Manufacturers
-
Start with planning. Involve a toxicologist at the R&D stage to form a Biological Evaluation Plan (BEP).
-
Do not economize on chemical analysis. The completeness of extraction and method sensitivity must match clinical use conditions (body temperature, enzymatic activity of biological media).
-
Validate in vitro methods. Use only methods approved by the OECD and recognized by national regulators.
-
Monitor pharmacopoeial changes. Harmonization of EAEU pharmacopoeias introduces adjustments to solubility requirements and material purity classes.
Expert Commentary
"The toxicology of medical devices is undergoing a tectonic shift: we are moving from phenomenology ('it turned red / didn't turn red') to quantitative chemical-biological modeling. Today, a manufacturer must think in terms of a 'permissible dose' for a specific use scenario. It is the toxicological risk assessment, not a single cytotoxicity test, that is becoming the dominant feature proving safety over the product's entire lifecycle," notes the head of the biological research department at one of the leading accredited EAEU laboratories.
This news piece underscores that toxicological research is not a bureaucratic burden, but the intellectual and ethical foundation of the medical device industry, ensuring the trust of the healthcare system and patient protection.
